CMS Proposes Major MA & Part D Overhaul for 2027

Medicare policy rarely shows up like a summer blockbuster. It usually arrives with a PDF, a deadline, and enough acronyms to make your coffee give up. But CMS’s proposed Medicare Advantage and Part D overhaul for 2027 is not a tiny housekeeping tweak. It is a broad attempt to reshape how plan quality is measured, how beneficiaries respond to provider network changes, how the Inflation Reduction Act’s Part D redesign gets locked into regulation, and how the agency thinks about competition, risk adjustment, and administrative burden.

In plain English, CMS is trying to do three things at once. First, it wants Medicare Advantage and Part D to look simpler and more consumer-friendly on the surface. Second, it wants payment and quality incentives to focus more on outcomes and less on paperwork theater. Third, it is clearly signaling that larger battles are coming over coding, health equity, special needs plans, broker oversight, and even whether nutrition and well-being should play a bigger role in the future of Medicare Advantage.

That combination is why this proposal matters. It is not just about changing a few rules before the next plan year. It is about where CMS thinks the program is headed next, and whether that future will feel more helpful to beneficiaries or just more complicated in a different font.

Why this proposal landed with such a thud

The size of Medicare Advantage explains the drama. MA is no longer a side option for a niche slice of Medicare. It now covers more than 35 million people, and the average beneficiary in 2026 can still choose from dozens of MA prescription drug plans, even though plan offerings have tightened and some enrollees have faced terminations, consolidations, or narrower choices. That means any rule touching quality scores, payments, networks, or pharmacy coverage can ripple through a huge share of the Medicare market.

And that is exactly what the 2027 cycle does. It also helps to know that people often lump two separate CMS actions into one giant regulatory casserole. The proposed rule focuses on policy and technical changes for MA and Part D, including Star Ratings, enrollment rules, marketing, supplemental benefits, and codifying IRA-related Part D changes. The Advance Notice, released separately, deals with payment methodology, risk adjustment, and annual Part D benefit parameters. Different documents, same anxiety.

If you felt tempted to read all of it in one sitting, first of all, brave. Second, the real story is simpler than it looks.

The biggest proposed change: a Star Ratings reboot

CMS made Star Ratings the headliner, and that makes sense. Star Ratings influence how beneficiaries compare plans and affect Quality Bonus Payments and rebates for Medicare Advantage contracts. In the proposal, CMS argues that the ratings system has become too cluttered with measures that either capture administrative processes, show very little variation across plans, or offer limited value to shoppers trying to tell one plan from another.

1) CMS wants to stop the Excellent Health Outcomes for All reward

One of the most notable moves is CMS’s proposal not to implement the Excellent Health Outcomes for All reward, previously called the Health Equity Index reward, for the 2027 Star Ratings. Instead, the agency proposed keeping the older historical reward factor that recognizes steady, high performance across measures.

That may sound like a dry statistical swap, but it carries real policy meaning. The previous health equity-focused reward was designed to create stronger incentives for plans to perform well for enrollees with social risk factors. By stepping back from that structure, CMS signaled that it wanted a simpler methodology and broader incentives across all enrollees, rather than a separate reward design tied to subpopulations. Supporters see that as simplification. Critics see it as a retreat from targeted equity incentives. Both readings are fair, which is why this proposal got attention fast.

2) CMS proposed removing 12 Star Ratings measures

CMS also proposed removing 12 measures from the Star Ratings program and replacing some of that administrative weight with a more focused clinical orientation. The agency’s pitch is straightforward: if a measure is topped out, highly administrative, or too noisy to help a beneficiary distinguish between plans, maybe it should not sit in the shopping window pretending to be a crystal ball.

The measure cuts span administrative, process, and patient experience categories. CMS and outside analysts described the shift as an attempt to refocus ratings on clinical care, outcomes, and patient experience where meaningful performance differences still exist. The move could reduce burden for plans, but it also raises a valid concern: when you remove measures, you may reduce clutter, but you can also remove signals that advocates and regulators use to spot trouble.

3) A new depression screening measure points to behavioral health

To avoid making the whole exercise feel like a subtraction problem, CMS also proposed a new Depression Screening and Follow-Up measure for Part C. That addition is small compared with the broader overhaul, but it matters. It suggests CMS still wants Star Ratings to reward preventive care and behavioral health integration, especially in primary care settings where depression too often goes unnoticed until life gets significantly harder.

In other words, CMS is not abandoning measurement. It is trying to pick fewer battles and make those battles count more.

Enrollment changes: continuity of care moves to center stage

Another proposed change would have made life easier for beneficiaries dealing with provider network disruptions. CMS proposed modifying the special enrollment period tied to provider terminations so beneficiaries could change plans when a provider leaves the network without first needing CMS and the plan to label the change “significant.”

That idea reflects a very real problem. To a patient in active treatment, it does not matter whether a network change looks statistically significant in a spreadsheet. If your oncologist, cardiologist, or neurologist disappears from your plan midyear, the disruption feels significant immediately, often before lunch.

The proposal also aimed to codify existing CMS policy on certain special enrollment periods that require prior approval, which CMS framed as a transparency and stability measure. The beneficiary-friendly message was clear: fewer gray zones, clearer rules, and less dependence on bureaucratic interpretation when continuity of care is on the line.

A quick current-context note: after the comment period, CMS did not finalize the provider-termination special enrollment period in April 2026. Even so, the proposal revealed that the agency recognizes midyear provider exits as a major consumer pain point, and the topic is unlikely to disappear.

Part D in 2027: the IRA redesign gets welded into regulation

The Part D piece of the proposal may be less flashy, but it is arguably more important for beneficiaries who actually use expensive medications. The Inflation Reduction Act made major changes to Part D, and CMS had temporary authority through 2026 to implement much of that redesign through program instructions. For 2027 and beyond, the agency proposed codifying those changes into the rules.

That includes the elimination of the old coverage gap phase, the lower annual out-of-pocket structure, zero cost sharing in the catastrophic phase, and the Manufacturer Discount Program that replaced the old Coverage Gap Discount Program. CMS also proposed codifying related updates to True Out-of-Pocket calculations, specialty-tier rules, reinsurance payment methodology, and the Selected Drug Subsidy.

This matters because the beneficiary experience of Part D is not just about annual savings headlines. It is about whether costs feel predictable at the pharmacy counter, whether plan systems apply discounts correctly, whether formularies stay usable, and whether the redesign actually reduces confusion instead of creating a newer, shinier kind of confusion.

The companion Advance Notice supplied the 2027 math behind that experience. CMS projected a standard deductible of $700 and a standard out-of-pocket threshold of $2,400 for 2027. For beneficiaries with complex medication needs, those numbers are not trivia. They shape plan choice, monthly budgeting, and that familiar ritual of staring at a drug price screen like it just personally offended you.

The other big story: payment, coding, and risk adjustment

Although the proposed rule handled policy changes, the separate 2027 Advance Notice supplied the payment storyline that sent the industry into spreadsheet mode. CMS projected a very slim net average payment increase of 0.09%, or a little over $700 million, before accounting for underlying MA risk score growth driven by coding and population change. When coding trend is considered, CMS said the expected average change in payments would be 2.54%.

The real tension was inside the components. CMS proposed a -3.32% impact from risk model revision and normalization and another -1.53% from excluding diagnoses reported only through unlinked chart review records from risk score calculations. That is policy-speak for this: CMS is trying to make payment more closely track real beneficiary health risk and less closely track diagnosis-capture strategies that do not necessarily reflect better care.

Brookings and other analysts saw this as part of a broader effort to revisit how Medicare Advantage risk adjustment works, including questions about encounter data, utilization-based models, and whether future reforms can reduce coding intensity without creating new distortions. Avalere highlighted another important point on the Part D side: CMS proposed separate RxHCC model segments for MA-PDs and standalone PDPs, a move intended to improve predictive accuracy because the two markets do not behave exactly the same.

For insurers, this is the section of the rule cycle that causes people to refresh actuarial models repeatedly and eat lunch at their desks. For beneficiaries, it matters because payment accuracy eventually influences premiums, supplemental benefits, network decisions, and plan participation.

Three RFIs that quietly preview the future

Sometimes the most revealing part of a rule is not the text that changes law right away. It is the part where CMS asks questions. The 2027 proposal included three major requests for information, and together they read like a sneak preview trailer for the next few seasons of Medicare policy.

Risk adjustment and quality bonus modernization

CMS asked for feedback on future changes to risk adjustment and quality bonus payments, including ideas that could use artificial intelligence, alternative data, or more encounter-based methods. That does not mean AI is about to run Medicare like an overly confident intern with a dashboard. It does mean CMS is actively considering deeper structural reform.

C-SNP growth and dual-eligible enrollment

CMS also zeroed in on the rapid growth of chronic condition special needs plans, especially when dually eligible individuals enroll in those plans instead of D-SNPs that are specifically designed around Medicare-Medicaid integration. The agency floated the possibility of requiring more Medicaid contract-like structures for certain C-SNPs or I-SNPs that enroll high numbers of dual eligibles.

That is a big deal because dual-eligible beneficiaries often need care coordination that is not merely nice to have. It is the difference between a health plan that feels connected and one that feels like three customer service departments arguing through a wall.

Well-being and nutrition

The third RFI asked about well-being and nutrition policy in MA. This is the kind of topic that can sound soft until you remember how often poor nutrition, social isolation, and weak preventive care show up as hard, expensive medical problems later. CMS is clearly exploring whether future MA incentives should do more to support nutrition and broader well-being, not just disease treatment after the wheels wobble.

Deregulation, marketing, and health equity rollbacks

Not every proposed change was about adding or modernizing. A significant portion focused on removing requirements that CMS described as duplicative, burdensome, or no longer necessary. That included rescinding the midyear notice requirement about unused supplemental benefits, eliminating health disparity activities from MA quality improvement program requirements, and removing certain health equity expectations for utilization management committees.

CMS also proposed loosening a number of marketing and agent-broker rules. Outside summaries highlighted changes affecting TPMO disclaimers, the timing of broker scripts, the 48-hour Scope of Appointment requirement, educational-event restrictions, superlative language in marketing, and call-record retention expectations. The argument for these changes is that the prior framework had become too rigid and sometimes interfered with ordinary beneficiary conversations.

The counterargument is obvious. For many Medicare beneficiaries, especially those with chronic illness, cognitive limitations, or low health literacy, these “administrative” protections are not abstract. They shape how clearly people understand plan choices, whether they are misled, and how easily they can preserve continuity of care. National Health Council comments captured that concern well: simplification can help, but not if it strips away patient-relevant quality signals or weakens guardrails people rely on when choosing coverage.

What this proposal would mean for beneficiaries

For beneficiaries, the proposal cuts in two directions at once.

On the positive side, the rule tries to make plan comparison more focused, codify the new Part D drug benefit rules, and potentially improve continuity of care when providers leave networks. It also invites future thinking around nutrition, integrated care, and more accurate payment structures that could support longer-term sustainability.

On the uncertain side, fewer Star Ratings measures may make it harder to detect some plan performance differences. Pulling back on certain health equity requirements may reduce plan burden, but it could also limit formal accountability for disparities. Looser marketing rules could make beneficiary outreach more flexible, or more confusing, depending on who is doing the talking.

So the proposal is not a simple story of “less regulation good” or “more measurement good.” It is a negotiation over what kind of Medicare Advantage and Part D program CMS wants to reward: one that is cleaner on paper, one that is more clinically focused, and one that may be less prescriptive about some oversight tools than the last round of rulemaking.

Real-world experiences: what this overhaul could feel like in practice

The examples below are composite experiences based on the kinds of issues raised by CMS, beneficiary advocates, and market analyses.

Imagine a 72-year-old beneficiary with diabetes, heart disease, and depression who chose a Medicare Advantage plan because it offered dental, vision, and drug coverage in one package. Under today’s environment, that person may never think about Star Ratings methodology, but they absolutely notice when a favorite doctor leaves the network, when a pharmacy claim processes incorrectly, or when plan materials make it hard to understand what changed from last year. For a person like that, the 2027 proposal is not really about rulemaking jargon. It is about whether the system gets easier to live with.

Now picture a daughter helping her father compare plans during open enrollment. She uses Plan Finder, looks at Star Ratings, checks whether his specialists are in network, and tries to estimate his drug costs without needing a second spreadsheet and a stress nap. If CMS succeeds in simplifying Star Ratings while keeping the measures that actually matter, that shopping experience could improve. If too many useful signals disappear, plan comparison could become cleaner but less informative, like a restaurant menu that tells you everything is “chef-inspired” and nothing else.

There is also the pharmacy counter experience. Beneficiaries with cancer, rheumatoid arthritis, multiple sclerosis, or other high-cost conditions often experience Part D through repeated, high-stakes transactions. They do not care whether a cost-sharing protection arrived through a statute, a subregulatory memo, or codified regulation. They care whether the number they are quoted is right, whether the benefit phase is clear, and whether the drug is actually available when the prescription is needed. CMS’s push to codify the IRA redesign matters because it can make those protections feel more durable and less temporary.

For brokers and agents, the proposal would also feel real. Many beneficiaries depend on human guidance, not because they enjoy phone calls with disclaimers, but because MA and Part D choices can be maddeningly detailed. More flexibility in marketing rules may help legitimate agents serve people faster and more naturally. At the same time, weaker or looser guardrails could create more room for sloppy sales tactics. The beneficiary experience will depend less on the rule’s intent and more on how CMS monitors bad actors after giving the good actors more room to breathe.

And then there is the plan side. Operational teams inside MA and Part D organizations would read this proposal as a clear demand to pivot. Less emphasis on certain administrative measures means fewer points for looking organized on paper. More emphasis on meaningful outcomes means plans may need to invest more in clinical coordination, behavioral health workflows, and member experience. In that sense, the proposal is a cultural message as much as a technical one: stop winning the spreadsheet Olympics and show more evidence that care is actually working for people.

Final takeaway

CMS’s proposed 2027 MA and Part D overhaul is best understood as a reset, not a routine tune-up. The agency wants a more streamlined Star Ratings system, a more durable and codified Part D redesign, a more aggressive conversation about risk adjustment and coding, and a lighter regulatory footprint in selected areas ranging from health equity mandates to marketing rules.

That mix will please some stakeholders and unsettle others, which is usually a sign that the proposal is doing something consequential. The biggest question is not whether the rule is “major.” It plainly is. The bigger question is whether CMS can simplify the program without blurring the information and safeguards beneficiaries still need. Medicare policy works best when it feels boring in the best possible way: clear choices, stable access, predictable drug costs, and fewer nasty surprises. The 2027 proposal claims that is the destination. The implementation details will decide whether the ride gets smoother or just takes a different route through the same traffic.